Brokerages Set Geron Corporation (NASDAQ:GERN) PT at $2.17

Shares of Geron Corporation (NASDAQ:GERN) have earned an average rating of “Hold” from the seven research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $2.1667.

Several equities analysts have weighed in on GERN shares. UBS Group reissued a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Geron in a research report on Wednesday, January 28th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a research note on Thursday, January 29th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th.

Institutional Trading of Geron

A number of large investors have recently made changes to their positions in the company. 55 North Private Wealth LLC bought a new position in Geron during the fourth quarter worth about $29,000. LCM Capital Management Inc increased its holdings in shares of Geron by 80.6% in the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC acquired a new stake in shares of Geron during the fourth quarter worth about $33,000. Caitong International Asset Management Co. Ltd raised its position in shares of Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 24,410 shares during the period. Finally, Swiss Life Asset Management Ltd lifted its holdings in shares of Geron by 73.6% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 11,182 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Stock Performance

Shares of NASDAQ:GERN opened at $1.51 on Friday. The stock has a market capitalization of $967.22 million, a P/E ratio of -11.62 and a beta of 0.58. The company has a current ratio of 4.66, a quick ratio of 3.62 and a debt-to-equity ratio of 0.53. Geron has a 1-year low of $1.04 and a 1-year high of $2.01. The business has a 50-day moving average price of $1.55 and a two-hundred day moving average price of $1.37.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.02). Geron had a negative net margin of 46.65% and a negative return on equity of 28.86%. The company had revenue of $48.02 million during the quarter, compared to analyst estimates of $50.43 million. Equities analysts predict that Geron will post -0.25 earnings per share for the current year.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.